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Abstract
Bacteria active against multi-drug resistant pathogens, isolated by direct selection of colo-
nies from clover silage samples, produce zones of inhibition against two Gram-negative
(Klebsiella pneumoniae Ni9 and Pseudomonas aeruginosa MMA83) and two Gram-positive
(Staphylococcus aureus ATCC25923 and Listeria monocytogenes ATCC19111) patho-
gens. Isolates BGSP7, BGSP9, BGSP11 and BGSP12 produced the largest zones of
inhibition against all four pathogens when grown in LB broth with aeration at 37˚C. Isolates
BGSP7, BGSP9, BGSP11 and BGSP12 were identified as Brevibacillus laterosporus and
pulsed field gel electrophoresis and extracellular protein profiles showed that three different
strains (BGSP7, BGSP9 and BGSP11) were isolated. A semi-native SDS-PAGE (sodium
dodecyl sulphate-polyacrylamide gel electrophoresis) gel overlay assay showed that
BGSP7 and BGSP9 produce small antimicrobial molecules of about 1.5 kDa, while
BGSP11 produces antimicrobial molecules of 1.5 and 6 kDa active against S. aureus
ATCC25923. Amino acid analysis of two antimicrobial molecules (1583.73 Da; from BGSP7
and 1556.31 Da; from BGSP11) revealed that they have a similar composition and differ
only by virtue of the presence of a methionine which is present only in BGSP11 molecule.
Genome sequencing of the three isolates revealed the presence of gene clusters associated
with the production of non-ribosomally synthesized peptides (brevibacillin, bogorol, gramici-
din S, plipastatin and tyrocin) and bacteriocins (laterosporulin, a lactococcin 972-like bacteri-
ocin, as well as putative linocin M18, sactipeptide, UviB and lantipeptide-like molecules).
Ultimately, the purification of a number of antimicrobial molecules from each isolate sug-
gests that they can be considered as potent biocontrol strains that produce an arsenal of
antimicrobial molecules active against Gram-positive and Gram-negative multi-resistant
pathogens, fungi and insects.
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Introduction
The acquisition and spread of antibiotic resistance among pathogenic bacteria poses a great
threat to public health, especially in light of the paucity of new antibiotics being developed [1].
Consequently, there is a need for new antimicrobials that can be used as alternatives to con-
ventional antibiotics. Antimicrobial peptides and bacteriocins are considered as such potential
alternatives [2, 3]. Bacteriocins are ribosomally synthesized peptides with antimicrobial activ-
ity produced by many bacterial species. In most cases, bacteriocins inhibit the growth of closely
related bacteria, although some exhibit a broad inhibitory spectrum against food-spoilage and
pathogenic bacteria [4]. The vast majority of these molecules are initially synthesized intracel-
lularly as larger inactive precursors, and many of them are further subjected to different enzy-
matic modifications, such as cyclization, glycosylation and the introduction of lanthionine and
beta-methyl lanthionine [5]. According to the latest classification scheme, bacteriocins can be
divided into three main groups [2, 6]. Class I are represented by antimicrobial peptides that
have been enzymatically modified; Class II, which encompasses non-modified or minimally
modified peptides, that are further divided into several subgroups; Class III, containing the
large, unmodified heat sensitive antimicrobial proteins with bacteriolytic or some other mech-
anism of action.
Bacteria from the genus Bacillus and related genera produce many substances with antimi-
crobial activity, including non-ribosomally synthesized peptides and lipopeptides [7–9], poly-
ketide compounds [10] and bacteriocins. Indeed, Bacillus strains produce bacteriocins from
all three classes [11]. Class I representatives are subtilin, ericin A, ericin S, mersacidin, paeni-
bacillin, sublancin 168 [11, 12], haloduracin, lichenicidin and subtilosin A [13–15]. Class II
bacteriocins found in Bacillus strains include coagulin, produced by Bacillus coagulans [16],
lichenocin 50.2, produced by B. licheniformis VPS50.2 [17] and others [18]. In Bacillus, class
III is represented by large proteins that have enzymatic activity, such as the megacin family of
bacteriocins produced by strains of Bacillus megaterium [18–20].
Antagonistic compounds produced by bacteria from the genus Brevibacillus have also been
studied in recent years [21] and strains of Brevibacillus laterosporus are well known producers
of antibacterial and antifungal agents [22–24]. They are considered an important tool for bio-
logical control because of their biopesticidal properties against insects and nematodes [25, 26].
The recently characterized Br. laterosporus OSY-I1 produces brevibacillin, a 1583 Da antimi-
crobial lipopeptide with a linear structure containing 13 amino acids and a C6 fatty acid at the
N-terminus [27]. Brevibacillin shows strong antimicrobial activity against some pathogenic
and food-spoilage Gram-positive bacteria, particularly methicillin resistant Staphylococcus
aureus, Listeria monocytogenes and Bacillus cereus. The mechanism of action of this molecule
is most likely based on its amphiphilic nature and the ability of the cationic amino acids to
interact with the negatively charged phospholipids of the cell membrane, causing the disrup-
tion and depolarization of the membrane [27]. A similar mechanism was observed in the case
of paenibacterin, a broad-spectrum antimicrobial lipopeptide produced by Paenibacillus thia-
minolyticus [28]. In addition, it was found that the marine bacterial isolate Brevibacillus later-
osporus PNG-276 showed broad-spectrum antibiotic activity (producing polyketides the
basiliskamides A and B and nonribosomal peptides: loloatins A-D and bogorols A-E) against
the human pathogens MRSA, VRE, Mycobacterium tuberculosis, Candida albicans, and Escher-
ichia coli [29].
From a bacteriocin perspective, laterosporulin is an example of a class IId bacteriocin pro-
duced by strain GI-9, preliminarily identified as Br. laterosporus [30]. Laterosporulin is active
against both Gram-positive and Gram-negative bacteria and was found to be resistant to a
range of proteolytic enzymes. Structural studies revealed that the peptide consists of twisted
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β-sheet and includes three disulfide bonds [31]. Laterosporulin is relatively rich in cysteine
and polar amino acids, which is atypical for bacteriocins in general, whereas its structure
showed similarities with mammalian defensins. More recently, laterosporulin 10, produced by
the strain Brevibacillus sp. SKDU10 was characterized [32] and, while considered similar,
shows only 57.6% identity with laterosporulin. In addition, this novel bacteriocin has a differ-
ent antimicrobial spectrum to laterosporulin as activity is limited to Gram-positive bacteria.
However, laterosporulin 10 has also proven to be a promising new anti-cancer molecule that
exhibits a cytotoxic effect on cancer cells [33].
A number of Br. laterosporus strains have been sequenced and their genomes deposited in
Genbank. These include LMG 15441 (under accession number AFRV00000000, [34]), GI-9
(under accession numbers CAGD01000001 to CAGD01000061, [35]), B9 (under accession
numbers CP011074-CP011076, [36]), Lak 1210 (under accession number NDIP00000000,
[37]), OSY-I1 (under accession number NOLX00000000, [38]), DSM25 (accession number
ARFS00000000), ZQ2, UBA5783, DSM25, PE36 (accession number NZ_AXBT00000000.1)
and Uniss_18.
The current study focused on the isolation of new cultivable bacteria that produce natural
antimicrobial molecules effective against multidrug resistant pathogens of humans, animals
and plants, regardless of their taxonomy. This approach lead to the characterization and deter-
mination of the antimicrobial activity of three new isolated strains of Br. laterosporus from
silage in order to determine their potential as biocontrol agents.
Materials and methods
Bacterial strains and culture conditions
Strains used in this study are listed in Table 1. Achromobacter, Acinetobacter, Burkholderia,
Erwinia, Escherichia, Klebsiella, Pseudomonas, Salmonella and Staphylococcus strains were
grown in Luria Bertani (LB) medium at 37˚C with aeration, while Agrobacterium, Bacillus,
Chromobacterium, Ralstonia and Xanthomonas strains were grown in the same medium at
30˚C with aeration. Enterococcus, Lactococcus, and Listeria strains were grown in M17 medium
(Merck GmbH, Darmstadt, Germany) supplemented with D-glucose (0.5% w/v) (GM17) at
30˚C. Lactobacillus strains were grown in MRS medium (Merck GmbH, Darmstadt, Germany)
at 30˚C. Streptococcus strains were grown in Brain Heart Infusion (BHI) medium (Oxoid,
Basingstoke, Hampshire, England) at 37˚C and an atmosphere of 5% CO2. Paenibacillus larvae
was grown in Mueller Hinton broth (Oxoid, Basingstoke, Hampshire, England) supplemented
with yeast extract (1.5% w/v), K2HPO4 (0.3% w/v), D-glucose (0.2% w/n), sodium pyruvate
(0.1% w/n) and 0.1 mg/l of thiamine at 30˚C. The bioactive compounds-producing isolates,
Br. laterosporus BGSP7, BGSP9, BGSP11 and BGSP12 were isolated from a sample of clover
silage, taken from a household in a village Stari Tamisˇ, near Pančevo, Serbia. Optimal growth
conditions of Br. laterosporus BGSP7, BGSP9 and BGSP11 strains (medium, optimal tempera-
ture, aeration), were determined by growing a 1% inoculum of overnight culture (small-scale 5
ml) in different growth media (LB, minimal medium (M9) with glucose, BHI, GM17 and
MRS) at different temperatures and aeration by monitoring the absorbance OD600 at every
hour of growth. For surface sliding mobility assays, minimal medium (MSgg) as described pre-
viously by Branda et al. [39] was used. Solid medium and soft agar were made by adding 1.5%
or 0.7% (w/v) agar (Torlak, Belgrade, Serbia) to the liquid media, respectively. The following
antibiotic concentrations were used: erythromycin, 10 μg/ml (lactococci and B. subtilis 168)
and 300 μg/ml (E. coli); tetracycline, 20 μg/ml (E. coli); and ampicillin, 100 μg/ml (E. coli). The
5-bromo-4-chloro-3-indolyl-β-D-galacto-pyranoside (X-Gal) (Fermentas, Vilnius, Lithuania)
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Table 1. Bacterial strains used in this study.
Strains, plasmids and derivatives Source or reference
Achromobacter xylosoxidans MS4 [40]
Acinetobacter baumannii 6077/12 [41]
Agrobacterium tumefaciens LMM collection
Bacillus cereus ATCC11778 ATCC collection
Bacillus pumilis BGSP1-2 This study
Bacillus pumilis BGSP2-2 This study
Bacillus pumilis BGSP3-1 This study
Bacillus pumilis BGSP3-3 This study
Bacillus pumilis BGSP5-2 This study
Bacillus subtilis 168 [42]
Brevibacillus laterosporus BGSP7 This study
Brevibacillus laterosporus BGSP9 This study
Brevibacillus laterosporus BGSP11 This study
Brevibacillus laterosporus BGSP12 This study
Burkholderia cepacia [42]
Burkholderia glumae [42]
Chromobacterium violaceum LMM collection
Enterococcus faecalis ZLS10-27 [43]
Erwinia carotovora [42]
Escherichia coli ATCC25922 ATCC collection
Escherichia coli DH5α [44]
Escherichia coli HB101 [45]
Klebsiella pneumoniae Ni9 [46]
Lactobacillus paracasei BGSJ2-8 [47]
Lactobacillus plantarum 9208 [48]
Lactobacillus zeae [48]
Lactococcus cremoris MG7284 [49]
Lactococcus lactis BGBU1-4 [50]
Lactococcus lactis HP Laboratory collection
Lactococcus raffinolactis BGTRK10-1 [51]
Listeria monocytogenes ATCC19111 ATCC collection
Paenibacillus larvae Faculty of Veterinary Medicine,
University of Belgrade, Serbia
Pseudomonas aeruginosa MMA83 [52]
Pseudomonas syringae LMM collection
Ralstonia pickettii 666 LMM collection
Salmonella enteritidis ATCC13706 ATCC collection
Staphylococcus aureus ATCC25923 ATCC collection
Streptococcus agalactiae B165 Laboratory “Paster”, Belgrade, Serbia
Streptococcus mutans BGSF1 [53]
Streptococcus pneumoniae P173 Laboratory “Paster”, Belgrade, Serbia
Streptococcus pyogenes A2941 Laboratory “Paster”, Belgrade, Serbia
Streptococcus thermophilus LMM collection
Xanthomonas oryzae LMM collection
ATCC—American Type Culture Collection;
LMM collection—Collection of Laboratory for Molecular Microbiology, Institute of Molecular Genetics and Genetic
Engineering, University of Belgrade, Serbia.
https://doi.org/10.1371/journal.pone.0216773.t001
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was added to LB medium plates for blue/white color screening of colonies with cloned frag-
ments at a final concentration 40 μg/ml (E. coli).
Sample collection, screening and isolation of producers of antimicrobial
molecules
Samples of soil (5), silage (2) and fermented vegetables (13) were collected for the isolation of
bacterial producers of antimicrobials active against pathogens. One gram of each sample was
suspended in 50 ml of physiological solution (8.9 g/l NaCl) and incubated at room temperature
in an orbital shaker at 200 rpm for 30 min. Mixtures were allowed to settle and serial dilutions
up to 10−5 were prepared using sterile physiological solution. Isolation of bacteria from these
mixtures was done by spreading serial dilutions of each sample on five different growth media
in quadruplicate (LA, M9A, BHIA, GM17A and MRSA) and plates incubated at 30 and 37˚C
for 48 hours. The Petri dishes with grown colonies (50–300) were overlaid with soft agar con-
taining four different multi-drug resistant pathogenic indicator strains (two Gram-negative
pathogens: K. pneumoniae Ni9, P. aeruginosa MMA83 and two Gram-positive pathogens: S.
aureus ATCC25923, L. monocytogenes ATCC19111) and plates incubated overnight at the
appropriate temperatures. Colonies producing antimicrobial molecules were detected by the
appearance of a zone of inhibition around the colonies. Purification of antimicrobial produc-
ers was achieved by repeated streaking of single colonies from the center of inhibition zones
on the medium from which it was originally selected. The ability of the purified isolates to pro-
duce inhibitory molecules and their spectrum of activity was tested by the agar well diffusion
assay as described previously [54]. Briefly, 50 μl aliquots of sample (culture or filtered superna-
tant) were assayed in wells pre-made in soft agar, and indicator plates were incubated under
appropriate conditions for the respective indicator strain. A clear zone of inhibition around
the wells following 24h of incubation was taken as evidence of antimicrobial production. To
monitor the kinetics of antimicrobial production/activity 100 ml of fresh pre-warmed LB
broth was inoculated with overnight culture (1% v/v) and incubated at 37˚C with aeration.
Samples were taken every hour from 0 to 16h and at 24h for determination of OD600 and anti-
microbial activity by the agar well diffusion assay (using cell free supernatants of cultures)
where S. aureus ATCC25923 and P. aeruginosa MMA83 were used as indicator strains. To
confirm the proteinaceous nature of antimicrobial molecules, a crystal of the proteolytic
enzyme, pronase E, (Sigma, St. Louis, MO, USA) was placed close to the edge of the potential
antimicrobial compound containing well and reduction of activity was taken as confirmation.
Molecular masses of bioactive peptides were estimated by Tricine-SDS-PAGE (sodium
dodecyl sulphate-polyacrylamide gel electrophoresis) 15% acrylamide gels [55]. The position
of the active peptides was determined by comparing the position of the zone inhibition (on
overlaid part of the gel with LB soft agar containing indicator strain S. aureus and incubated
overnight at 37˚C) with protein bands on the part of the stained gel with Coomassie brilliant
blue R-250.
Identification of isolates with antimicrobial activity
Identification of selected isolates was done by testing their morphological and biochemical
characteristics. Taxonomic determination of isolates was done initially by 16S rRNA gene
sequencing [56], and confirmed by genome sequencing. Platinum Taq DNA Polymerase High
Fidelity (Thermo Fisher Scientific, Waltham, MA, USA) was used to amplify the gene for 16S
rRNA using a GeneAmp PCR System 2700 thermal cycler (Applied Biosystems, Foster City,
CA, USA) under the conditions listed in S1A Table. PCR products were checked on a 1% aga-
rose gel (at a constant voltage of 80 V) and purified using a Thermo Scientific PCR Purification
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Kit (Thermo Scientific, Lithuania) according to the manufacturer’s protocol and sequenced
and identified by using BLAST.
Pulse field gel electrophoresis (PFGE) was performed for isolates comparison and for strain
determination, as described previously [57] using NotI macro-restriction polymorphism.
Effect of temperature, pH and enzymes on antimicrobial activity
Antimicrobial molecules concentrated from culture supernatant using 50% ammonium sul-
phate saturation were tested for: thermal stability by incubation at 60, 80, 100 and 121˚C for 15
and 30 min; for pH resistance by adjusting pH from 2–12 and incubating for 1 h at 37˚C fol-
lowed by neutralisation to pH 7 for 30 min at room temperature; for resistance to different
enzymes (trypsin, pepsin, α-chymotrypsin, proteinase K, pronase E, lysozyme, lipase and α-
amylase) samples of antimicrobial molecules were incubated in buffered conditions and tem-
perature appropriate for enzymes for 1h and 24h as described previously [54]. After treat-
ments, antimicrobial activity was determined by agar well diffusion assay, as described above
using S. aureus ATCC25923 and L. monocytogenes ATCC19111 indicator strains; untreated
bacteriocin samples were used as a control. All experiments were done in triplicate.
The potency of purified bacteriocin like inhibitory substances (stored at 4, 37 and 45˚C)
were checked at regular intervals 0, 1, 2, 3, 4, 5, 6 and 12 months against sensitive indicators by
the agar well diffusion method.
Purification of antimicrobial molecules produced by Br. laterosporus
strains and partial characterisation by amino acid analysis
One liter aliquots of BGSP7, BGSP9 and BGSP11 were grown overnight in LB broth which
had been passed through a column containing Amberlite XAD 16 to remove hydrophobic
peptides which can interfere with purification. Cultures were centrifuged (8000 rpm, 10˚C, 20
min) and antimicrobial molecules purified from both cells (i) and supernatant (ii); (i) the cell
pellet was mixed with 200 ml of 70% propan-2-ol 0.1% TFA (IPA) and stirred for 3–4 h at
RT. The resulting suspension was centrifuged (8000 rpm, 10˚C, 20 min) and cell supernatant
retained for purification. The IPA was removed from the cell extract and it was applied to a 5g,
20 ml Strata-E C18 SPE column (Phenomenex, Cheshire, UK) pre-equilibrated with methanol
and distilled water. The column was washed with 30 ml of 30% ethanol followed by 30 ml of
70% IPA. Eluents were assayed for antimicrobial activity by agar well diffusion using Lactococ-
cus lactis HP as the indicator strain. In next step, the IPA was removed from the active eluent
and it was applied to a semi prep C12 Proteo column running a 25–50% gradient where buffer
A was 0.1% TFA and buffer B 100% acetonitrile 0.1% TFA. Eluent was monitored at 214 nm
and fractions were collected at 1 min intervals. Fractions were assayed on L. lactis HP indicator
plates; (ii) the culture supernatant was passed through an Econo column containing 30g
Amberlite XAD16 beads pre-washed with 300 ml of distilled water. The column was washed
with 300 ml of 35% ethanol and the inhibitory activity eluted in 300 ml of 70% IPA and
retained. The IPA was removed from the XAD IPA eluent and it was further purified by C18
SPE and Reversed Phase HPLC as described for the cell extract.
Total amino acids analysis of the 1583.73 Da antimicrobial molecule purified from BGSP7
cells and the 1556.31 Da antimicrobial molecule purified from BGSP11 supernatant were
determined using a Biochrom 30+ Automatic Amino Acid Analyzer (Biochrom, Cambridge,
UK) provided by Institute of Food Technology, University of Novi Sad, Serbia. Hydrolysis of
purified antimicrobial molecules with 5 N HCl and preparation of samples for amino acid
composition analysis were performed as recommended by manufacturer (Biochrom, Cam-
bridge, UK).
Antimicrobials from new Brevibacillus laterosporus strains
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Determination of minimum inhibitory concentrations (MICs) for the two
most abundant antimicrobial molecules
Micro-dilution assays were done with the 1583.73 Da antimicrobial molecule from BGSP7
and the 1556.31 Da molecule from BGSP11 against indicator organisms (listed in Table 1)
as described previously [58]. All indicator strains were diluted to 0.5 McFarland units from
which 20 μl were distributed in wells of a clear 96-well flat bottom microtiter plate. Antimicro-
bial molecules from BGSP7 and BGSP11 (resuspended at 1 mg/ml in water) were two-fold
serially diluted to give a dilution series from 250 μg/ml to 7.8 μg/ml. Medium (blanks) and
untreated culture were included as controls. The microtiter plates were incubated at 37˚C for
24 h, and the optical densities at 595 nm (OD595) recorded (Infinite M200pro, Tecan, Switzer-
land). All experiments were performed in triplicate.
DNA manipulations
Genomic DNA was extracted by the method described previously [59] with minor modifica-
tions: logarithmic phase cells were pre-treated with lysozyme (4 mg/ml, for 15 min at 37˚C)
prior to treatment with 2% SDS. Plasmids from Br. laterosporus, B. subtilis and L. lactis were
isolated by the method described by O’Sullivan and Klaenhammer [60]. For plasmid isolation
from E. coli, a Thermo Fisher Scientific GeneJET Plasmid Miniprep kit was used according to
the manufacturer’s recommendations (Thermo Scientific, Lithuania). Digestion with restric-
tion enzymes was conducted according to the supplier’s instructions (Thermo Fisher Scientific
Waltham, MA, USA). The DNA fragments from agarose gels were purified using QIAqick Gel
extraction kit as described by the manufacturer (Qiagen, Hilden, Germany). DNA was ligated
with T4 DNA ligase (Agilent technologies, USA) according to the manufacturer’s recommen-
dations. Standard heat-shock transformation was used for plasmid transformation of E. coli
[44]. L. lactis subsp. cremoris MG7284 was transformed with plasmid constructs by electropo-
ration using a method described by Holo and Nes [61] with modifications specified in [62].
Bacillus subtilis 168 was transformed by plasmid DNA constructs after induction of compe-
tence by the method described by Bennallack et al. [63].
Real time quantitative PCR (RT-qPCR)
Total RNA was isolated from bacterial cells during different growth phases of Br. laterosporus
BGSP7, BGSP9 and BGSP11 using the RNeasy Mini kit (Qiagen). The residual DNA was
digested using an Ambion DNA free Kit (Thermo Fisher Scientific, MA, USA). Isolated RNA
was quantified using a NanoDrop spectrophotometer (GE Healthcare, Life Science) and integrity
was analyzed on a 1.2% formaldehyde-agarose gel. The first-strand of cDNA was synthesized
with a RevertAid RT Reverse Transcription Kit according to the enzyme manufacturer instruc-
tions (Thermo Fisher Scientific, MA, USA), using 1 μg of isolated RNA as a template. Random
hexamers (Applied Biosystems) and RiboLock RNase inhibitor (Thermo Scientific) were used in
the reactions. The qPCR was carried out using the KAPA SYBR Fast qPCR Kit (KAPA Biosys-
tems, MA, USA) in a 7500 Fast Real-Time PCR System (Applied Biosystems) under the condi-
tions and appropriate pairs of primers listed in S1C Table. The results were normalized to the
reference rpoD gene. The obtained Ct values from log phase of bacterial growth were set as cali-
brators and all results were expressed as relative target abundance using the 2-ΔΔCt method [64].
Construction of a cosmid library and screening for clones carrying
bacteriocin operons
Total genomic DNA isolated from BGSP7, BGSP9 and BGSP11 was partially digested with
EcoRI restriction enzyme. Digestion was carried out at room temperature (ca. 23˚C) and,
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during incubation, samples were collected at different time points and EDTA immediately
added to a final concentration 10 mM (pH 8) to stop digestion. pLAFR3 cosmid vector was
used for construction and the cosmid library was digested with the same restriction enzyme,
dephosphorylated and ligated with partially digested total DNA. Ligation was checked for
formed concatemers of high molecular weight on 1% agarose gel electrophoresis (at a constant
voltage of 80 V) before encapsulation into phage particles using a packaging kit (Agilent tech-
nologies). Encapsulated cosmids were transfected into E. coli HB101 cells prepared in 10 mM
MgSO4. Clones were selected on LA plates containing tetracycline 20μg/ml.
Cosmid libraries were screened for cosmids carrying cloned bacteriocin gene clusters for
laterosporulin and lactococcin 972-like bacteriocins using colony PCR under the conditions
listed in S1B Table. Specific sets of primers for laterosporulin and lactococcin 972-like bacteri-
ocin genes were used; one pair of primers for laterosporulin and second pair for lactococcin
972-like bacteriocin genes from all three strains (BGSP7, BGSP9 and BGSP11) were designed
according to comparative analysis of their sequences. For PCR analysis from each cosmid
library (BGSP7, BGSP9 and BGSP11) 550 colonies were randomly chosen. The size of the frag-
ments cloned into the cosmid vector was analysed on 1% agarose gels (at a constant voltage of
80 V), after digestion with EcoRI to compare the presence of common fragments. Positively
selected colonies (pcosLS7, pcosLS9, pcosLS11, pcosLC7, pcosLC9, and pcosLC11) were fur-
ther tested after DNA isolation using the QIAprep Spin Miniprep kit (Qiagen GmBH, Hilden,
Germany) to possess the entire gene cluster for the corresponding bacteriocin by the PCR
method. From restriction enzyme analysis of genome sequences using DNA Strider3 program
it was found that the entire gene clusters for both bacteriocins are located within the EcoRI
restriction fragments of different lengths (laterosporulin: BGSP7-6738 bp, BGSP9-6739 bp,
BGSP11-6750 bp; lactococcin 972-like bacteriocin: BGSP7-8532 bp, BGSP9-5749 bp, BGSP11-
7217 bp). Corresponding EcoRI restriction fragments were subcloned to pAZIL (giving corre-
sponding constructs named as pAZIL-ELS7, pAZIL-ELS9, pAZIL-ELS11, pAZIL-ELC7, pAZI-
L-ELC9 and pAZIL-ELC11) and pA13 vectors (giving corresponding constructs named as
pA13-ELS7, pA13-ELS9, pA13-ELS11, pA13-ELC7, pA13-ELC9 and pA13-ELC11) that were
confirmed by sequencing and stored for further experiments.
DNA sequencing and sequence analysis
Amplified fragments and constructs were sequenced by Macrogen sequencing service (Macro-
gen Europe, Amsterdam, Netherlands). Sequence annotation and a database search for
sequence similarities were completed using the BLAST program of the National Center for
Biotechnology Information—NCBI [65]. The DNA Strider3 program was used for open read-
ing frame (ORF) and restriction enzyme prediction.
Complete genome sequencing and annotation
The genome sequences of Br. laterosporus BGSP7, BGSP9 and BGSP11 were determined using
the Illumina HiSeq platform by MicrobesNG service (MicrobesNG, IMI-School of Biosciences,
University of Birmingham, Birmingham, UK). Draft genome sequences of Br. laterosporus
BGSP7, BGSP9 and BGSP11 have been deposited in GenBank under accession numbers:
GCA_002927075.1, GCA_002927085.1 and GCA_002926995.1, respectively.
Results
Isolation of strains with antimicrobial activity
From approximately 20,000 colonies isolated from samples of soil, clover and corn silage and
fermented vegetables, 22 colonies were chosen as potential producers of antimicrobial
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molecules active against at least one of four tested multi-drug resistant pathogenic strains. It
was found that cultures and cell free supernatant of four isolates (BGSP7, BGSP9, BGSP11 and
BGSP12) from clover silage showed the strongest inhibitory activity against all four indicator
strains, producing zones of inhibition of 20 mm (Fig 1). A further 5 isolates showed inhibitory
effects against S. aureus ATCC25923 and L. monocytogenes ATCC19111 only with zones of
inhibition of 15 mm, while 13 isolates did not show inhibition in the repeated antimicrobial
test.
Isolate BGSP11 produced the largest zones of inhibition against all tested indicator
strains (Fig 1). Interestingly, after three days, BGSP9 and especially BGSP11 showed antimi-
crobial activity in waves of concentric circles of different size. BGSP7 does not display this
behavior (Fig 2A). This may indicate that antimicrobial molecules from BGSP9 and BGSP11
strains are active against non-dividing cells of S. aureus ATCC25923 during stationary
phase or successively synthesize various antimicrobial molecules exhibiting different diffu-
sion capacities through agar. In addition, strain BGSP11 forms radial bridges consisting of
tendril-like fibers (Fig 2B). Since these strains, especially BGSP11, showed motility, their
ability to move on a semi-solid surface was tested. Previously it has been demonstrated that
B. subtilis can use sliding motility to colonize surfaces, using a tendril-like fiber-based
growth mode when various macronutrients or micronutrients are limiting [66]. We
tested the ability of isolated strains to move on semi-solid medium and found that surface
colonization on defined semi-solid medium is dependent on potassium ion and agarose
Fig 1. Antimicrobial activity of Br. Laterosporus BGSP7 (1), BGSP9 (2), BGSP11 (3) and BGSP12 (4) strains on
different indicator strains: S. aureus ATCC25923 (A); L. monocytogenes ATCC19111 (B); P. aeruginosa MMA83
(C); K. pneumoniae Ni9 (D). Antimicrobial activity was analysed after overnight growth (16 h) of the indicator
strains.
https://doi.org/10.1371/journal.pone.0216773.g001
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concentration. At low KCl concentrations, strain BGSP7 showed the strongest swarming
motility, swarming over the surface with a more dendritic central colony and produced a
less robust surface film. Strain BGSP9 showed slower swarming movement on the surface at
low KCl concentration but formed a robust surface film compared to strain BGSP7. Strain
BGSP11 swarmed over the surface forming a robust film when the concentration of KCl is
high, while on medium with low KCl concentrations forms a very weak film without ten-
dril-like fibers (S1 Fig).
Identification of antimicrobial producing isolates
Phenotypic characterization and BLAST analysis of 16S rRNA gene sequence of nine antimi-
crobial producing isolates resulted in them being assigned to one of two groups: a) four iso-
lates/strains (BGSP7, BGSP9, BGSP11 and BGSP12) with strong antimicrobial activity against
all tested pathogens were classified as Br. laterosporus species (showing 98–99% identity with
Br. laterosporus strains NRRL-B-14295, HS-A-465 and CSS8); b) the other 5 isolates (BGSP1-
2, BGSP2-2, BGSP3-1, BGSP3-3 and BGSP5-2) with moderate antimicrobial activity were clas-
sified as Bacillus pumilus species (showing 97% identity with B. pumilus strains X3, HN-30 and
S10). The Br. laterosporus strains were selected for further characterization as they showed
much stronger and wider antimicrobial activity compared to the B. pumilus strains. Optimal
growth and production of inhibitory molecules for all four Br. laterosporus strains/isolates was
observed at 37˚C in LB medium with aeration. Plasmid isolation revealed that all four isolates
Fig 2. Antimicrobial activity of Br. laterosporus BGSP7 (1), BGSP9 (2) and BGSP11 (3) strains on S. aureus
ATCC25923 incubated for three days (A); Development of specific structures to over-bridge zone of inhibition by
Br. laterosporus BGSP11 strain in antimicrobial assay with Br. laterosporus strain BGSP7 (1), BGAP9 (2) and
BGSP11 (3) on sensitive strain S. aureus ATCC25923. Negative control (4) used in antimicrobial test: S. aureus
ATCC25923. Parts showing the antimicrobial activity of the strains were taken from the same Petri dish that was
incubated for five days (B).
https://doi.org/10.1371/journal.pone.0216773.g002
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contain small plasmids of similar size between 8 and 10 kb; isolates BGSP9 and BGS12 showed
the same plasmid profile (S2 Fig).
As all four Br. laterosporus strains/isolates (BGSP7, BGSP9, BGSP11 and BGSP12) showed
similar PFGE genotypes. Ultimately, among the four isolates, three distinct strains (BGSP7,
BGSP9 and BGSP11) were found to be present, as the BGSP9 and BGSP12 isolates showed
identical genomic DNA restriction (NotI) profiles (Fig 3).
Fig 3. Macrorestriction pattern analysis by pulsed field gel electrophoresis (PFGE) of Br. laterosporus BGSP7,
BGSP9, BGSP11 and BGSP12 strains using NotI restriction enzyme on 1.2% agarose gel.
https://doi.org/10.1371/journal.pone.0216773.g003
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Spectrum of activity of antimicrobial molecules produced by Br.
laterosporus BGSP7, BGSP9 and BGSP11 strains
The antimicrobial activity of overnight culture and crude extract from cell free supernatant
(50% saturation ammonium sulfate precipitate) was tested against various Gram-positive and
Gram-negative spoilage and pathogenic bacteria (listed in Table 1). Both, culture and crude
extract from supernatant of isolated strains (BGSP7, BGSP9 and BGSP11) significantly inhib-
ited the growth of all bacteria tested with the exception of Achromobacter xylosoxidans MS4,
indicating high inhibitory potential and a wide host range. Particularly strong antimicrobial
activity was exhibited against P. larvae, an organism that causes American foulbrood (AFB), a
destructive disease of honey bee colonies (S3 Fig).
Kinetics of antimicrobial production of Br. laterosporus BGSP7, BGSP9
and BGSP11 strains
It was found that antimicrobial production depends on the growth phase of strains BGSP7,
BGSP9 and BGSP11 (Fig 4). Inhibition of S. aureus ATCC25923 was achieved by components
produced after 1h of growth by all three strains, while production of the components that are
inhibitory for P. aeruginosa MMA83 begins after between 2 and 3h. Thereafter, the antimicro-
bial bioactivity of the BGSP7, BGSP9 and BGSP11 cultures increases against both indicator
strains, which correlates with increasing cell numbers in the logarithmic growth phase. The
production of antimicrobial components plateaus between 8 and 13h, which corresponds
from late logarithmic to early stationary phase. The antimicrobial bioactivity of BGSP7,
BGSP9 and BGSP11 strains on S. aureus ATCC25923 begins to decline after 13h, but at 24h it
is still effective. In contrast, the antimicrobial activity of BGSP7, BGSP9 and BGSP11 strains
against P. aeruginosa MMA83 rapidly decreases after 12h and at 16h has completely disap-
peared in strain BGSP9, while there is still a low level of activity in BGSP7 and BGSP11.
Heat, pH, enzymatic and storage stability of crude extract from cell free
supernatant
Crude antimicrobial extracts of all three strains showed similar characteristics, i.e., a) high heat
stability at 60, 80, 100, and 121˚C for 20 min, although treatment at 121˚C resulted in a smaller
zone of inhibition; b) sensitivity to proteolytic enzymes as evidenced by loss of antimicrobial
activity following pronase E treatment for 24 hours, partial reduction by trypsin, pepsin, α-
chymotrypsin and proteinase K and insensitivity to lysozyme, lipase and α-amylase confirmed
the proteinaceous nature of antimicrobials; c) stability over a wide pH range (2–14); d) antimi-
crobial activity was stable when stored for one year at 4˚C, while at 37˚C activity was lost after
three months, and at 45˚C was lost after one month.
SDS PAGE analysis of antimicrobial peptides produced by Br. laterosporus
BGSP7, BGSP9 and BGSP11
SDS PAGE analysis shows two clear zones of inhibition for strain BGSP11 and one zone for
BGSP7 and BGSP9 (Fig 5). Zones of inhibition corresponding to small molecular mass mole-
cule(s) (between 1–2 kDa) are evident for all three strains while, for strain BGSP11, an addi-
tional strong zone of inhibition corresponding to a mass of ~6 kDa was detected. The apparent
production of at least one additional antimicrobial by BGSP11 explains why this strain pro-
duces larger zones of inhibition relative to BGSP7 and BGSP9 (Fig 1). In addition, according
to extracellular protein profile of the strains (Fig 5) it can be concluded that isolates BGSP9
and BGSP12 are identical.
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Purification and molecular mass determination of antimicrobial molecules
produced by Br. laterosporus BGSP7, BGSP9 and BGSP11
Antimicrobial molecules were purified from both cells and supernatants of Br. laterosporus
BGSP7, BGSP9 and BGSP11 by Amberlite XAD (supernatant only), C18 solid phase extraction
Fig 4. Kinetics of antimicrobial production of Br. laterosorus BGSP7 (A), BGSP9 (B) and BGSP11 (C) strains
during the growth in LB medium at 37˚C. Growth of analyzed strains was monitored by measuring optical density at
OD600 (▲); Synthesis of antimicrobials was quantified by growth inhibition of S. aureus ATCC25923 (●) and P.
aeruginosa MMA83 (◆) by producer strains measured in millimeters of inhibition zone (mm).
https://doi.org/10.1371/journal.pone.0216773.g004
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and Reversed Phase HPLC. A number of HPLC fractions from each strain were active and
MALDI TOF mass spectrometry suggests that strains BGSP7, BGSP9 and BGSP11 produce
a number of small antimicrobial molecules of different molecular masses. Three common
molecular masses, i.e., 1557, 1570 and 1583 Da, are associated with the most active fractions
produced by all three strains (S4–S6 Figs).
Specifically, antimicrobial peptide masses purified from BGSP7 were (i) from cells: 1583.73
Da—which correlates with the main peak on the chromatogram and a minor 1568.83 Da pep-
tide (S4A Fig); (ii) from the supernatant: a 1583.94 Da mass again correlating with the most
dominant peak and a minor 1570 Da (S4B Fig). The most active antimicrobial molecules puri-
fied from BGSP9 was (i) from cells: 1571.64 Da (fractions 32–33; these were the most active
fractions and correlate with the biggest peak) and 1585.45 Da (S5A Fig); (ii) from supernatant:
1618.41 Da (fraction 24), 1555.79 and 1571.82 Da (fractions 25–27), 1557.19 Da (fraction 28),
1556.84, 1579.09 and 1603.16 (fractions 29–30), 1571.05 Da and 1603.22 (fractions 31–32)
and 1583.91 Da (fractions 33–36); (S5B Fig). Antimicrobial molecules purified from BGSP11
were (i) from cells: 1556.54 Da (fraction 36), 1571.05Da (fractions 37–41), 1584.56 Da
Fig 5. SDS-PAGE gel electrophoresis of proteins precipitated from supernatant of Br. laterosporus BGSP7,
BGSP9, BGSP11 and BGSP12 strains on 15% acrylamide gel stained with Coomassie Brilliant Blue (A); gel with
the same samples overlayed with LA-soft agar containing S. aureus ATCC25923 after incubation overnight at
37˚C (B).
https://doi.org/10.1371/journal.pone.0216773.g005
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(fraction 42), 1223.97 and 1274.78Da (fractions 56–57) (S6A Fig); (ii) from supernatant:
1636.18 Da (fraction 19), 1618.95Da (fractions 29–30), 1564.90 Da (fractions 31–33), 1556.31
Da (fractions 34–37), 1570.11 Da (fractions 38–40), 1584.62 Da (fractions 41–44), 1585.44
and 1598.19 Da (fractions 45–51) and 1223.92 and 1274.02 Da (fraction 57) (S6B Fig).
Based on the analysis of the molecular masses of active fractions, it can be concluded that the
strains produce number of different antimicrobial molecules of molecular mass ranging from
1223.21 to 1657.13 Da, wherein the following polypeptide antibiotics can be classified: tyroci-
dine (from 1269.6 to 1361.7 Da), plipastatin (1463.7 Da) [67] and lipopeptides like brevibacil-
lin (1583 Da), bogorols (A-1545, B-1570, C-1556, D-1602 and E-1618 Da) [27, 29] and Lh-1
of 1608.023 Da [68].
The most potent and abundant fractions, i.e., 1583.73 Da antimicrobial molecule from
BGSP7 and 1556.31 Da from BGSP11, were selected for amino acid composition analysis.
Amino acid analysis revealed that both peptides have a similar amino acid composition, but
differ by virtue of the presence of in methionine, which is found only in the 1556.31 antimicro-
bial from the BGSP11 strain (Table 2).
Minimal inhibitory concentrations (MICs) of purified antimicrobial
molecules required to inhibit selected indicators
The minimal inhibitory concentrations (MICs) of the two most abundant antimicrobial mole-
cules, 1583.73 Da from BGSP7 and 1556.31 Da from BGSP11, against a number of indicator
strains were determined. Both antimicrobial molecules showed strong antimicrobial activity
against all tested Gram-positive and Gram-negative strains, although small differences were
evident with respect to Achromobacter xylosoxidans MS4 (two times higher for antimicrobial
molecule of 1556.31 Da), Pseudomonas syringae (eight times higher for antimicrobial molecule
1583.73 Da) and Salmonella enteritidis ATCC13706 (two times higher for antimicrobial mole-
cule of 1556.31 Da) (Table 3).





Peptide of 1583.73 Da from fractions 39–41 from
cells wash of BGSP7 strain
Peptide of 1556.31 Da from fractions 34–37 from
supernatant of BGSP11 strain
Threonine (Thr—T) 101.105 - 0.0757
Serine (Ser—S) 87.078 0.1685 0.3528
Glutamic acid (Glu—E) 129.116 0.2693 0.8266
Proline (Pro—P) 97.117 0.5710 1.2604
Glycine (Gly—G) 57.052 0.0328 0.1684
Alanine (Ala—A) 71.019 0.0606 0.1885
Cysteine (Cys—C) 103.144 0.2046 0.5951
Valine (Val—V) 99.133 10.5905 10.9690
Methionine (Met—M) 131.198 0.1754 2.3586
Isoleucine (Ile—I) 113.160 6.0451 2.5983
Leucine (Leu—L) 113.160 11.9155 8.5396
Tyrosine (Tyr—Y) 163.170 9.1807 7.9586
Phenylalanine (Phe—F) 147.177 0.7485 1.1338
Histidine (His—H) 137.142 0.0614 -
Lysine (Lys—K) 128.174 12.7185 8.8001
Arginine (Arg—R) 156.188 0.0816 0.3034
Total amino acids 52.7422 45.8254
https://doi.org/10.1371/journal.pone.0216773.t002
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Comparative analysis of Br. laterosporus BGSP7, BGSP9 and BGSP11
genome sequences
The genomes of Br. laterosporus BGSP7, BGSP9 and BGSP11 were sequenced. The genomes
(5,335,373 bp—BGSP7; 5,801,339 bp—BGSP9 and 5,643,326 bp—BGSP11) consisted of one
chromosome and one circular plasmid of 9,427 bp (pBLSP7 of BGSP7), 9,158 bp (pBLSP9 of
BGSP9) or 8,578 bp (pBLSP11 of BGSP11), with a total GC content of about 40% (Table 4).






Achromobacter xylosoxidans MS4 158 316
Acinetobacter baumannii 6077/12 20 20
Agrobacterium tumefaciens 20 20
Bacillus cereus ATCC11778 5 5
Bacillus subtilis 168 5 5
Burkholderia cepacia 5 5
Burkholderia glumae 5 5
Chromobacterium violaceum 316 316
Enterococcus faecalis ZLS10-27 10 10
Erwinia carotovora 79 79
Escherichia coli ATCC25922 79 79
Klebsiella pneumoniae Ni9 316 316
Lactobacillus paracasei BGSJ2-8 5 5
Lactobacillus plantarum 9208 5 5
Lactobacillus zeae 5 5
Lactococcus cremoris MG7284 5 5
Lactococcus lactis BGBU1-4 5 5
Lactococcus raffinolactis BGTRK10-1 5 5
Listeria monocytogenes ATCC19111 5 5
Paenibacillus larvae 5 5
Pseudomonas aeruginosa MMA83 158 158
Pseudomonas syringae 158 20
Ralstonia pickettii 666 316 316
Salmonella enteritidis ATCC13706 158 31 6
Staphylococcus aureus ATCC25923 5 5
Streptococcus agalactiae B165 10 10
Streptococcus mutans BGSF1 5 5
Streptococcus pneumoniae P173 5 5
Streptococcus pyogenes A2941 5 5
Streptococcus thermophilus 5 5
Xanthomonas oryzae 316 316
https://doi.org/10.1371/journal.pone.0216773.t003
Table 4. Summary statistics for genome sequence assemblies.
Strain Assembly accession number Number of contigs Total length (bp) Number of genes Contig N50 (bp) G+C content (%)
BGSP7 GCA_002927075.1 111 5,335,373 4962 185,683 40.10
BGSP9 GCA_002927085.1 193 5,801,339 5313 117,738 40.24
BGSP11 GCA_002926995.1 157 5,643,326 5291 128,934 40.00
https://doi.org/10.1371/journal.pone.0216773.t004
Antimicrobials from new Brevibacillus laterosporus strains
PLOS ONE | https://doi.org/10.1371/journal.pone.0216773 May 10, 2019 16 / 30
Plasmids pBLSP9 and pBLSP11 showed a high degree of identity (93%), but only 27% with
plasmid pBLSP7. BLAST analysis found that pBLSP7 shares 88% of identity (on 60% coverage)
with plasmid pBRLA07 from Br. laterosporus LMG 15441, while plasmids pBLSP9 and
pBLSP11 showed 85% identity (on 40% coverage) with pBRLA07.
Comparative analysis of genomes shows that there are differences in both genome size and
consequently in the numbers of predicted genes. Strain BGSP7 possesses 197 genes that are
not present in BGSP9 and BGSP11 strains (S2A Table); BGSP9 strain possesses 228 genes
that are not present in BGSP7 and BGSP11 strains (S2B Table) and strain BGSP11 possesses
256 genes that are not present in BGSP7 and BGSP9 strains (S2C Table). These differences
may be responsible for strain specific phenotypic characteristics. Most of these differentially
present/absent genes are mobile elements, type I restriction-modification systems, phages and
hypothetical proteins. Among the genes that might plausibly contribute to the phenotypic dif-
ferences are, in strain BGSP7, a stage V sporulation protein, arsenate reductase and mosquito-
cidal toxin; in strain BGSP9, a lanthionine biosynthesis protein LanB, lanthionine biosynthesis
cyclase LanC and flagellar protein FlgJ; and in strain BGSP11, an oxetanocin A resistance pro-
tein, ferric siderophore transport system and a spore coat protein A.
Br. laterosporus BGSP7, BGSP9 and BGSP11 contain operons/gene clusters
predicted to encode the production of bacteriocins and secondary
metabolites
The genomes of all three strains were searched for the presence of secondary-metabolism bio-
synthesis genes using AntiSMASH (Antibiotics & Secondary Metabolite Analysis Shell) [69]
and BAGEL3 (identification of genes encoding bacteriocins and non-bactericidal post-transla-
tionally modified peptides) [70]. All three strains possess a number of genes that could possibly
encode known antimicrobial molecules. Results of AntiSMASH and BAGEL3 searches are
presented in Table 5 for all three strains. In addition, BLAST searches revealed that all three
strains possess candidate genes for production of the bacteriocin laterosporulin. The predicted
products of these genes showed 57% amino-acid identity (strain BGSP7) and 63% identity
(strains BGSP9 and BGSP11) with known laterosporulim proteins from Br. laterosporus GI-9
and LMG15441 (GenBank accession numbers: CCD21955.1 and AIG26526.1, respectively). A
search for genes encoding ribosomally synthesized antimicrobial peptides revealed that all
three strains had the potential to produce numerous bacteriocins in addition to laterosporulin,
lactococcin 972-like bacteriocin, linocin M18, LAPs, a sactipeptide, UviB and in addition
strain BGSP9 possesses genes for the synthesis of a lantipeptide (Table 5). The semi-native SDS
PAGE protein overlay antimicrobial assay suggests that only strain BGSP11 is able to produce
an antimicrobial molecule of about 6 kDa that could be bacteriocin laterosporulin.
Since all three strains produce non-ribosomally synthesized antimicrobial molecules
of molecular mass between 1.2 and 1.6 kDa (Fig 5), the genomes of all three strains were ana-
lyzed for the presence of synthase genes. It was found that all three strains possess numerous
synthase genes grouped/distributed into a number of gene clusters at different locations on the
genomes: the genomes of BGSP7, BGSP9 and BGSP11 strains possess 56, 70 and 56 synthase
genes, respectively (Table 6).
Brevibacillin is a potent 1583 Da antimicrobial lipopeptide produced by Br. laterosporus
OSY-I1 [27]. The brevibacillin gene cluster consists of five brevibacillin synthase genes (brvA,
brvB, brvC, brvD, brvE) and one ABC transporter gene (brvF) (Accession No. MF526970.1;
[38]. Since the most abundant antimicrobial molecule produced by strains BGSP7, BGSP9 and
BGSP11 was 1583 Da, the same mass as brevibacillin, genomes were searched for brevibacillin
synthesis gene cluster. The brevibacillin gene cluster was found in each of the three strains
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positioned between the rbbA gene for ribosome-associated ATPase and the topB gene for
DNA topoisomerase 3. Amino-acid identity between the synthase proteins is very high among
BGSP strains and also with those from strain OSY-I1 (between 96–99%) with the highest iden-
tity between BGSP7 strain and OSY-I1 (Fig 6). It is interesting to note that the strain BGSP9
possess an unusually large gene cluster of 99.8 kb on the chromosome, consisting of 16 genes
for polyketide synthases (PksB, PksE, PksM1, PksN1, PksL1, PksM2, PksL2, PksN2, AcpK,
PksF, PksG, PksH, PksI, PksM3, PksJ and PksR) unlike the other strains.
Table 5. Genome-based identification of novel molecules with antimicrobial activity by bioinformatic tools (AntiSMASH and BAGEL3).
Antimicrobial
molecule
Strain Detected by Amino Acid Sequence Identity (%) among
strains BGSP7, BGSP9
and BGSP11

























































Lantipeptide BGSP9 BAGEL3 MKKEDLFDLDVQVKEASQAQGDSVVSDLICTTFCSATFCQSNCC
https://doi.org/10.1371/journal.pone.0216773.t005
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Bacteriocin gene expression analysis by RT-qPCR
Genome analysis has shown that all three strains have numerous genes encoding for bacterio-
cin production, and the semi-native protein gel result (Fig 5) in combination with HPLC anal-
ysis has shown that all three strains synthesize small peptides. The SDS gel also suggests that
Table 6. Synthase genes present in genomes of Br. laterosporus BGSP7, BGSP9 and BGSP11 strains.
Synthase gene product Number of genes/products in chromosome of strains
BGSP7 BGSP9 BGSP11
Gramicidin S synthase 1 (GrsA) 2 2 2
Gramicidin S synthase 2 (GrsB) 12 12 12
Linear gramicidin synthase subunit B (LgrB) 2 3 2
Linear gramicidin synthase subunit D (LgrD) 3 2 2
Polyketide synthase (PksB) 1 2 1
Polyketide synthase (PksE) 1 2 1
Polyketide synthase (PksF) 1 2 1
Polyketide synthase (PksG) 1 2 1
Polyketide synthase (PksH) 1 2 1
Polyketide synthase (PksI) 1
Polyketide synthase (PksJ) 2 3 2
Polyketide synthase (PksL) 1 3 1
Polyketide synthase (PksM) 2 5 2
Polyketide synthase (PksN) 5 7 5
Polyketide synthase (PksR) 1 2 1
Polyketide biosynthesis acyl-carrier-protein (AcpK) 1 1 2
Phthiocerol/phenolphthiocerol synthesis polyketide synthase type I (PpsC) 2
Phthiocerol/phenolphthiocerol synthesis polyketide synthase type I (PpsE) 1
Polyketide biosynthesis protein (BaeE) 1 1 1
Plipastatin synthase subunit B (PpsB) 1 1 1
Plipastatin synthase subunit C (PpsC) 1 1 1
Plipastatin synthase subunit D (PpsD) 1 1 1
Plipastatin synthase subunit E (PpsE) 1 1
Surfactin synthase subunit 1 (SrfAA) 4 3 4
Tyrocidine synthase 3 (TycC) 8 10 10
EryA 1 1 1
Total number of genes / products 56 70 56
https://doi.org/10.1371/journal.pone.0216773.t006
Fig 6. Comparative analysis of brevibacillin gene cluster among Brevibacillus laterosporus strains. brvA—
brevibacillin synthetase A, brvB—brevibacillin synthetase B, brvC—brevibacillin synthetase C, brvD—brevibacillin
synthetase D, brvE—brevibacillin synthetase E, and brvF—brevibacillin ABC-transporter F genes.
https://doi.org/10.1371/journal.pone.0216773.g006
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strain BGSP11 produces a 6 kDa bacteriocin which is most probably latersporulin. Compara-
tive analysis of gene clusters revealed that there are some differences in the structural genes for
bacteriocin-like substances (Table 5). To elucidate if the structural genes are functional (tran-
scribed) the RT-qPCR method was performed using primers specific for each bacteriocin
structural gene (S1C Table). The relative expression level of each gene was calculated for each
growth phase (lag, exponential and stationary) in order to determine the level of bacteriocin
gene transcription during growth in LB medium. The RT-qPCR analysis of total RNA samples
from different growth phases show that the gene encoding the laterosporulin structural peptide
presented the highest level of transcription in 16h old culture for all three strains (more than
200-fold increase). In strains BGSP9 and BGSP11 there is direct correlation between growth
and laterosporulin gene transcription, while in strain BGSP7 there is a decrease in gene tran-
scription during exponential phase (Fig 7). Also, transcription of the genes for the synthesis of
Fig 7. Bacteriocin gene transcription analysis of Br. laterosporus BGSP7 (A); BGSP9 (B) and BGSP11 (C) by RT-
qPCR.
https://doi.org/10.1371/journal.pone.0216773.g007
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sactipeptides and lactococcin 972-like bacteriocin was significantly increased during the sta-
tionary phase in all three strains, with differences as transcription is gradually increased in
correlation with cell density for sactipeptides in strains BGSP7 and BGSP11 and for the laco-
coccin 972-like bacteriocin in BGSP11 strain, while transcription of genes for sactipeptides
and lacococcin 972-like bacteriocin in strain BGSP9 have reduced in exponential growth
phase and in strain BGSP7 transcription of gene for lacococcin 972-like bacteriocin is almost
completely absent in exponential growth phase. Transcription of the gene for the bacteriocin
linocin M18 has a negative correlation with the increase in cell density in all three strains. Sim-
ilar results for gene transcription were obtained for LAPs and UviB in all three strains. Tran-
scription of the lantipeptide gene in strain BGSP9 showed very high levels with the pattern of
increase in exponential and reduction in stationary phase of growth (Fig 7B). RTqPCR analysis
revealed that all selected bacteriocin genes present in Br. laterosporus BGSP7, BGSP9 and
BGSP11 strains are regulated on a transcription level in a growth phase-dependent manner.
Selection of clones carrying bacteriocin operons and expression in
heterologous hosts
Cosmid libraries of Br. laterosporus BGSP7, BGSP9 and BGSP11 strains were constructed and
analysis revealed that laterosporulin and lactococcin 972-like bacteriocin clusters seem to be
complete because they contained a structural gene, a hypothetical protein-most likely respon-
sible for immunity, two transporters and a transcription regulator and differ among the
strains. Cosmid clones, carrying bacteriocin genes clusters were cloned into vectors replicating
in Gram-positive bacteria (pAZIL for L. lactis and pA13 for B. subtilis) giving corresponding
constructs: pAZIL-ELS7, pAZIL-ELS9, pAZIL-ELS11, pAZIL-ELC7, pAZIL-ELC9 and pAZI-
L-ELC11, pA13-ELS7, pA13-ELS9, pA13-ELS11, pA13-ELC7, pA13-ELC9 and pA13-ELC11.
B. subtilis 168 and L. lactis subsp. cremoris MG7284 were chosen for heterologous expression
of laterosporulin and lactococcin 972-like bacteriocin gene clusters. B. subtilis 168 transfor-
mants were checked for enhanced antimicrobial activity on S. aureus ATCC25923 (since strain
B. subtilis 168 produces a cyclic peptide antibiotic, subtilosin A) and confirmed for plasmid
integrity after re-transformation of DH5α and by restriction enzyme analysis. Antimicrobial
activity of L. lactis subsp. cremoris MG7284 transformants against L. lactis subsp. cremoris
MG7284, S. aureus ATCC25923 and L. monocytogenes ATCC19111 was tested. None of the
transformants obtained in strains B. subtilis 168 and L. lactis subsp. cremoris MG7284 pro-
duced antimicrobial molecules indicating that cloned gene clusters are not expressed in the
heterologous hosts used for expression.
Discussion
The emergence of resistance to antibiotics, has created an urgent need for new antimicrobials
and has focused research in two directions i) towards the direct isolation of new bacterial iso-
lates with antimicrobial activity and ii) the analysis of metagenomes for the presence of genes/
operons with potential for novel antimicrobial production [71]. In this study, clover silage
samples were assayed for antipathogenic potential and three new Br. laterosporus strains
(BGSP7, BGSP9 and BGSP11) were isolated showing strong antimicrobial activity against
Gram-positive and Gram-negative food-borne spoilage and pathogenic bacteria from humans,
animals and plants. Members of the species Br. laterosporus do not cause disease or harmful
effects on humans, animals and plants and are even considered/used as probiotics [72]. The
bioactive compounds produced by Br. laterosporus SA14 include antimicrobial peptides which
are medically important substances that may be used for alternative treatment of MRSA infec-
tion [73]. This genus continues to be a source of numerous enzymes of great biotechnological
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interest due to their ability to biodegrade low density polyethylene and ability to act as a candi-
date biocontrol agent [22].
Silage is a common fermented ruminant food prepared from fresh grass or corn stalk. The
most frequent bacterial species that contribute to the quality and durability (shelf life) of silage
are lactobacilli and Brevibacillus, which most likely enter from the environment [74]. Antimi-
crobial molecules with narrow or broad spectrum activity are often produced by bacterial
strains to compete with other microbes, which inhabit the same ecological niches including
different strains of the same species. In recent years, research on Br. laterosporus strains has
intensified, as it is a non-pathogenic bacterium with the ability to synthesize a significant num-
ber of antimicrobial molecules. Recently, different antimicrobial peptides [18, 30, 32], lipopep-
tides [27, 67, 75] and cyclic dipeptides [76] have been isolated and characterized from strains
of Br. laterosporus with broad-spectrum antimicrobial activity. In this study we investigate
the antibacterial potential of three new isolated Br. laterosporus BGSP7, BGSP9 and BGSP11
strains from clover silage. All three strains show inhibitory activity towards a number of patho-
genic bacteria, without the emergence of resistant colonies even after several days of incuba-
tion. It is interesting that In addition, it has been observed that strains show cross inhibition,
even auto-inhibition was noticed (data not shown), which is most probably due to the synthe-
sis of a large number of diverse antimicrobial molecules. It is interesting that the period of the
inhibition of Gram-positive and Gram-negative bacteria by synthesized antimicrobial com-
pounds of isolated strains BGSP7, BGSP9 and BGSP11 is different (Fig 4) suggesting two
possibilities: that the synthesized molecule(s) have a different antimicrobial effect on various
bacteria as shown in the analysis of the MIC values for two of them (Table 3), or at different
time period are synthesized antimicrobial molecules of different specificities.
Crude cell free antimicrobial extracts (50% saturation of ammonium sulfate) from BGSP7,
BGSP9 and BGSP11 are stable across a wide temperature and pH range and during storage for
up to 1 year at +4˚C. These are desirable properties that can increase the potential applications
of the strains. It has been shown that laterosporulin, produced by Brevibacillus sp. strain GI-9
is thermostable, pH tolerant and resistant to proteolytic enzymes [30]. Purified brevibacillin
showed no sign of degradation when it was held at 80˚C for 60 min, and it retained at least
50% of its antimicrobial activity when it was held for 22h under acidic or alkaline conditions
[27].
It is interesting that the most abundant antimicrobial molecule of 1583 Da, purified from
BGSP7 shows low MIC values against Gram-negative pathogens unlike brevibacillin, which is
a lipopeptide of the same molecular mass [27] indicating differences in the molecule produced
by BGSP7. Two of the most potent and abundant fractions (one from BGSP7-1583.73 Da and
second from BGSP11-1556.31 Da) were analyzed by N-terminal amino acid sequencing that
failed because N-terminus was protected most likely due to the presence of a non-proteina-
ceous component. Total amino acid analysis was then performed and results revealed that the
amino acid content of the samples was 52.7422 and 45.8254% respectively suggesting the pres-
ence of non-proteinaceous components (Table 2). It is interesting that almost all antimicrobial
peptides and lipopeptides contain similar amino acids residues, specifically the aliphatic ami-
nio acids: Leu, Ile and Val, cationic: Lys and polar, aromatic: Tyr. Examples include gramicidin
(Val-Gly-Ala-Leu-Ala-Val-Val-Val-Trp-Leu-Tyr-Leu-Trp-Leu-Trp), tyrocidine cyclic deca-
peptide (DPhe-Pro-Phe-DPhe-Asn-Gln-Tyr-Val-Orn-Leu), plipastatin cyclodecapeptide
(Glu-Orn-Tyr-aThr-Glu-Ala/Val-Pro-Glu-Tyr-Ile), brevibacillin (FA-Dhb-Leu-Orn-Ile-Ile-
Val-Lys-Val-Val-Lys-Tyr-Leu-Valinol), bogorols (Hmp-Aba-Leu-Orn-Ile-Val-Val-Lys-Val-
Leu-Lys-Tyr-Leu-Valinol) laterocidin (Tyr-Pro-Phe-Phe-Asn-Asp-Leu-Val-Orn-Leu), surfac-
tin (Glu-Leu-Leu-Val-Asp-Leu-Leu/Ile) and iturin (Asn-Tyr-Asn-Glu-Asn-Ser) [21, 29]. It is
not possible to determine the sequence of the antimicrobial molecules from the amino acid
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analysis results of these two fractions, but the presence and ratio of amino acids indicates that
the strains produce similar, but not identical antimicrobial molecules to those previously
described. This is particularly evident for the 1556.31 Da antimicrobial molecule produced by
strain BGSP11 as it contains the amino acid methionine which presence has been detected
only in bogorols D and E, both of which of different molecular mass (1602 and 1618 Da,
respectively) [29]. BGSP strains isolated from silage produce novel mutually similar complex
antimicrobial molecules that differ slightly in amino acid composition. It is demonstrated that
changes in amino acid composition of LsbB bacteriocin can drastically affect activity [77]. In
addition to the differences in the protein portion, the antimicrobial molecules could also differ
in the non-protein part, so that a greater variety of molecules can be expected among isolated
strains. Because of the similar molecular mass and amino acid composition, we assume that
most of the antimicrobial molecules produced by BGSP strains are lipoproteins similar to bre-
vibacillin [27] or bogorol variants [29]. Determining the sequence of different antimicrobial
molecules purified from BGSP strains by LC MS/MS and structure using nuclear magnetic res-
onance (NMR) will be the subject of future research.
Powerful molecular mining approaches using bioinformatics tools (e.g., AntiSMASH and
BAGEL3) are available for identification of genetic determinants of antimicrobial produc-
tion. [78]. Zhao and Kuipers [18] provided a classification scheme of known and putative
antimicrobial compounds produced by a wide variety of Bacillales species using web based
genome-mining prediction tools. In order to fully study the antimicrobial potential of iso-
lated strains, we applied two approaches: a) complete genome sequencing applying both
AntiSMASH and BAGEL3 searches for the presence of genes (operons, gene clusters) encod-
ing antimicrobials and b) purification of antimicrobials from culture supernatant and the
cell surface. The genome search showed that all three strains had the potential to produce
numerous antimicrobials including bacteriocins, non-ribosomally synthetized polypeptides
and lipopeptides. A purification approach confirmed that BGSP strains produce a large num-
ber of small molecular mass antimicrobials (between 1200–1600 Da) and strain BGSP11
seems to produces one bacteriocin of about 6 kDa, which is most likely laterosporulin that
shows only 57% identity with GI-9 strain. It is possible that the 6 kDa zone of inhibition pro-
duced by strain BGSP11 on the SDS gel could be due to multimerization of lipopeptide anti-
microbial molecules, as noted by the Alajlani and coauthors [79] in Bacillus subtilis strain
BIA, since N terminal sequencing of the protein band failed. The transcriptional analysis
of the genes for the synthesis of bacteriocins showed that they were all transcribed, but that
the transcription was regulated in a growth phase-dependent manner. In order to overcome
this problem, we cloned gene clusters for two bacteriocins (laterosporulin and lactococcin
972-like bacteriocin) and tried to express them in the heterologous host, but it was unsuc-
cessful. Singh and coauthors [30] also tried to express a 4 kb fragment carrying laterosporulin
gene cluster from Brevibacillus sp. strain GI-9, also unsuccessfully, indicating that most
probably there are other host factors involved in the expression. The next approach that we
plan to apply will be mutagenesis or phage induction, that may trigger bacteriocin synthesis
as demonstrated by Brady and coauthors [80]. Among Brevibacillus species genetic manipu-
lations are well developed for Br. choshinensis strains and it is used as Gram positive expres-
sion system (Takara Brevibacillus expression system). According to our best knowledge tools
for genetic manipulations in Br. laterosporus are still lacking, but since many strains possess
plasmids that can be used for the construction of tools/vectors for cloning, expression and
mutagenesis and because of the importance of these bacteria there is a need for its develop-
ment. Plasmids from BGSP strains showed homology (at different levels) with only one plas-
mid characterized in strains of Br. laterosporus (pBRLA07) indicating their different origins.
An additional characteristic of Br. laterosporus strains, which makes them suitable for genetic
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manipulation, is an exceptional antibiotic sensitivity (less than or about 1 μg/ml for erythro-
mycin, chloramphenicol and tetracycline).
In addition to antibacterial activity, strains of Brevibacillus are well known producers of
antifungal agents [22] and they are also active against insects and nematodes [25, 26]. Br. later-
osporus is an invertebrate pathogen that is characterized by a unique spore coat and canoe-
shaped parasporal body (SC-CSPB) complex surrounding the core spore. Some of the proteins
associated with the spore coat, exosporium and CSPB complex represent putative virulence
factors acting against insects. In addition, these proteins are progressively synthetized during
bacterial growth, a proportional increase in the insecticidal activity of this bacterium was
observed, being fully toxic when the spore envelopes are completely formed [81]. Preliminary
results obtained on potato beetle (Leptinotarsa decemlineata) indicate that BGSP7, BGSP9
and BGSP11 strains show a high degree of antagonism, both against larval forms and adults,
although BGSP11 strain shows the highest efficacy, most probably because it possesses an
additional spore coat protein A (unpublished data). It is well known that some strains of Br.
laterosporus are highly toxic for mosquitoes [82] because they produce crystalline inclusions of
various shapes and sizes [83]. The genome search revealed that strain BGSP7 possesses a gene
for mosquitocidal toxin that could be involved in anti-insecticidal activity. Preliminary tests
performed on a limited number of pathogenic fungi have shown that strains BGSP7, BGSP9
and BGSP11 have the potential to inhibit the growth of several pathogenic fungi (unpublished
data).
Based on the results obtained in this study it can be concluded that novel strains of Br. later-
osporus BGSP7, BGSP9 and BGSP11 produce a number of antimicrobial molecules that are
active against various Gram-positive and Gram-negative pathogens of humans, animals and
plants with MIC values lower than nisin for many strains used in analysis and represent good
candidates for isolation and application of various novel antimicrobial molecules (bacteriocins,
antimicrobial peptides, lipopeptides and polyketides), as well as for biological control.
Supporting information
S1 Fig. Surface colonization by Br. laterosporus BGSP7, BGSP9 and BGSP11 strains on
defined semi-solid media is dependent on the level of potassium ion and agarose concen-
tration. Semi-solid MSggN agarose plates (0.3 to 1.5% w/v agarose and 100 μM or 5 mM KCl)
were inoculated in the center with 2μl of culture of the strains (in triplicate). After growth for
24 h at 37˚C, typical plates were photographed.
(TIF)
S2 Fig. Gel electrophoresis of plasmid DNA isolated from Br. laterosporus BGSP7, BGSP9,
BGSP11 and BGSP12 on 1% agarose gel containing ethidium bromide (200 μg/ml) photo-
graphed under UV light.
(TIF)
S3 Fig. The agar well diffusion assay. Antimicrobial activity of Br. laterosporus BGSP7 (3),
BGSP9 (4) and BGSP11 (5) strains on P. larvae PC19726256. Negative control P. larvae
PC19726256 (1) and nisin producer L. lactis (2) as positive control, were used.
(TIF)
S4 Fig. Reverse-phase high-performance liquid chromatography (RP-HPLC) chromato-
gram from the cell wash (A) and supernatant (B) from BGSP7 strain. Matrix-assisted laser
desorption ionization–time of flight (MALDI-TOF) mass spectrometry data from the fractions
33–36; 1568.83 Da (Aa), fractions 37–41; 1583.73 Da (Ab), fractions 29–42; 1583.94 Da (Ba),
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fractions 56–57; 1569.87 (Bb).
(TIF)
S5 Fig. Reverse-phase high-performance liquid chromatography (RP-HPLC) chromatogram
from the cell wash (A) and supernatant (B) from BGSP9 strain. Matrix-assisted laser desorp-
tion ionization–time of flight (MALDI-TOF) mass spectrometry data from the fractions 24–25;
1657.53 Da (Aa), fraction 28; 1611.46 Da (Ab), fraction 29; 1557.37 Da (Ac), fraction 30; 1625.44
and 1603.16 Da (Ad), fractions 32–33; 1571.64 Da (Ae), fractions 34–36; 1585.45 Da (Af), frac-
tion 24; 1618.41 Da (Ba), fractions 25–27; 1571.82 and 1555.79 Da (Bb), fraction 28; 1557.19 Da
(Bc), fractions 29–30; 1579.09,1556.84 (Bd) and 1603.16 Da (Be), fractions 31–32; 1571.05 and
1603.22 Da (Bf), fractions 33–36; 1583.91 Da (Bg) and fraction 37; 1584.86 Da (Bh).
(TIF)
S6 Fig. Reverse-phase high-performance liquid chromatography (RP-HPLC) chromato-
gram from the cell wash (A) and supernatant (B) from BGSP11 strain. Matrix-assisted laser
desorption ionization–time of flight (MALDI-TOF) mass spectrometry data from the fraction
36; 1556.54 Da (Aa), fractions 37–41; 1571.05 Da (Ab), fractions 42–44; 1584.56 Da (Ac), frac-
tions 56–57; 1223.97 (Ad) and 1274.78 Da (Ae), fraction 19; 1636.18 Da (Ba), fraction 29–30;
1618.95 Da (Bb), fractions31-33; 1564.90 Da (Bc), fractions 34–37; 1556.31 (Bd), fractions
38–40; 1570.11 Da (Be), fractions 41–44; 1584.62 Da (Bf), fractions 45–51; 1585.44 (Bg) and
1598.19 Da (Bh) and fraction 57; 1274.02 and 1223.92 Da (Bi).
(TIF)
S1 Table. Primers used in this study. (A) Primers and PCR conditions used for identification
of isolates with antimicrobial activity. (B) Primers and PCR conditions used for screening cos-
mid libraries of BGSP7, BGSP9 and BGSP11. (C) Primers and conditions used in RT-qPCR.
(DOCX)
S2 Table. List of genes specific for each strain of Br. laterosporus isolated in this study (A) List
of genes present in Br. laterosporus BGSP7 genome which are absent in BGSP9 and BGSP11
genomes. (B) List of genes present in Br. laterosporus BGSP9 genome which are absent in
BGSP7 and BGSP11 genomes. (C) List of genes present in Br. laterosporus BGSP11 genome
which are absent BGSP7 and BGSP9 genomes.
(DOCX)
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